+ +

•  

   

     Microtiter wells were coated with human immunoglobulins with various isotypes. P16103 was used as primary antibody and peroxidase conjugated goat anti-mouse IgG was used as the secondary antibody. Result: P16103 does not cross-react with human IgG1, IgG2, IgG3, IgA, IgM and IgE.    

  
  

•  

   

     Lane 1: 100 ng of human IgG1 ;  Lane 2: 100 ng of human IgG2;  Lane 3: 100 ng of human IgG3;Lane 4: 100 ng of human IgG4;  Lane 5: 100 ng of human IgA ;  Lane 6: 100 ng of human IgM ;  Lane 7: 100 ng of human IgE ;  Result: P16103 can specifically detect human IgG4 by Western blotting;    

  
  

•  

   

     IHC-P analysis of human tonsil tissue by anti-human IgG4 antibody (P16103) IHC-P was performed using sections of the formalin-fixed paraffin-embedded human tonsil tissue;Result: Squamous epithelial cells and non-germinal center cells are positively stained at cytoplasm.    

  
  

The STX8 antibody targets Syntaxin-8 (STX8), a member of the SNARE (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) protein family. SNARE proteins mediate intracellular membrane fusion events critical for vesicle trafficking, organelle dynamics, and cargo transport. STX8 is primarily localized to endosomal compartments and plays a role in endosome maturation, lysosomal degradation, and autophagosome-lysosome fusion. It interacts with other SNAREs, such as VAMP7 and SNAP-23. to form complexes that drive membrane docking and fusion.

Research on STX8 has expanded due to its involvement in cellular processes linked to neurodegenerative diseases, cancer, and immune regulation. For instance, disrupted STX8 function has been associated with impaired autophagy in Alzheimer’s disease and lysosomal storage disorders. In cancer, altered STX8 expression may influence tumor progression by modulating secretory pathways or growth factor trafficking.

STX8 antibodies are essential tools for studying these mechanisms. They enable detection of STX8 expression via Western blotting, immunofluorescence, or immunoprecipitation, helping to map its subcellular distribution and interactions. Polyclonal and monoclonal STX8 antibodies are available, often validated in model systems like HeLa cells or knockout controls. Their specificity and applications vary, requiring careful selection based on experimental needs. Continued interest in STX8 highlights its potential as a therapeutic target or biomarker in disease contexts.